Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 7, 2014; 20(37): 13582-13590
Published online Oct 7, 2014. doi: 10.3748/wjg.v20.i37.13582
Published online Oct 7, 2014. doi: 10.3748/wjg.v20.i37.13582
Table 2 Laboratory assessments and anti-hepatitis B virus treatments administered to patients with hepatitis B virus infection, and the responses to treatment n (%)
HBV(n = 2562) | HBV and HCV(n = 42) | |
Laboratory assessments: | ||
HBsAg positive1 | 2195/2207 (99.5) | 32/35 (91.4) |
HBeAg positive1 | 971/2137 (45.4) | 5/34 (14.7) |
HBeAb positive1 | 1056/2092 (50.4) | 26/32 (81.3) |
HBV DNA positive1 | 1278/2286 (55.9) | 313/38 (34.2) |
ALT abnormal | 944 (36.8) | 19 (45.2) |
AST abnormal | 740 (28.9) | 16 (38.1) |
AFP abnormal | 142/866 (16.3) | 4/22 (18.2) |
Received antiviral treatment | 1490 (58.2) | 22 (52.4) |
Latest antiviral therapies | (n = 1490) | (n = 22) |
Interferon (IFN) | 109 (7.3) | 2 (9.1) |
PEG-IFN | 99 (6.6) | 14 (63.6) |
Lamivudine | 467 (31.3) | 4 (18.2) |
Telbivudine | 238 (16.0) | 1 (4.5) |
Adefovir dipivoxil | 691 (46.4) | 4 (18.2) |
Entecavir | 230 (15.4) | 2 (9.1) |
Duration of completed treatment, months, median (IQR) | (n = 1309) | (n = 21) |
11.2 (0-187.8) | 7.8 (0.6-69.6) | |
Responses to treatment | (n = 801) | (n = 12) |
Virological response2 | 645 (80.5) | 11 (91.7) |
Biochemical response3 | 465 (58.1) | 5 (41.7) |
Serological response4 | 105 (13.1) | 2 (16.7) |
Treatment status5 | ||
Sustained response6 | 5/38 (13.2) | 0 |
Virological breakthrough | 20/801 (2.5) | 0 |
- Citation: Sun YT, Zhang YX, Tang H, Mao Q, Wang XZ, Zhang LY, Chen H, Zhong YN, Lin SM, Zhang DZ. Clinical characteristics and current management of hepatitis B and C in China. World J Gastroenterol 2014; 20(37): 13582-13590
- URL: https://www.wjgnet.com/1007-9327/full/v20/i37/13582.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i37.13582